Skip to content

Warenkorb

Der Warenkorb ist leer.

Gesamt (exkl. MwSt.) £0,00
Warenkorb überprüfen & bezahlen
Antikörper

RUNX1 (Acetyl Lys24) rabbit pAb

Produktgrößen
50UL
£ POA
ES20054-50UL
100UL
£ POA
ES20054-100UL
Über dieses Produkt
SKU:
ES20054
Zusätzliche Namen:
Runt-related transcription factor 1 (Acute myeloid leukemia 1 protein;Core-binding factor subunit alpha-2;CBF-alpha-2;Oncogene AML-1;Polyomavirus enhancer-binding protein 2 alpha B subunit;PEA2-alpha B;PEBP2-alpha B;SL3-3 enhancer factor 1 alpha B subunit;SL3/AKV core-binding factor alpha B subunit)
Anwendung:
Western Blot, ELISA
Klonalität:
Polyclonal
Konzentration:
1 mg/ml
Weitere Details:
alternative products:Additional isoforms seem to exist;caution:The fusion of AML1 with EAP in T-MDS induces a change of reading frame in the latter resulting in 17 AA unrelated to those of EAP.;disease:A chromosomal aberration involving RUNX1/AML1 is a cause of chronic myelogenous leukemia (CML). Translocation t(3;21)(q26;q22) with EAP; MSD1 or EVI1.;disease:A chromosomal aberration involving RUNX1/AML1 is a cause of chronic myelomonocytic leukemia. Inversion inv(21)(q21;q22) with USP16.;disease:A chromosomal aberration involving RUNX1/AML1 is a cause of M2 type acute myeloid leukemia (AML-M2). Translocation t(8;21)(q22;q22) with RUNX1T1/MTG8/ETO.;disease:A chromosomal aberration involving RUNX1/AML1 is a cause of therapy-related myelodysplastic syndrome (T-MDS). Translocation t(3;21)(q26;q22) with EAP; MSD1 or EVI1.;disease:A chromosomal aberration involving RUNX1/AML1 is found in childhood acute lymphoblastic leukemia (ALL). Translocation t(12;21)(p13;q22) with TEL. The translocation fuses the 3'-end of TEL to the alternate 5'-exon of AML-1H.;disease:A chromosomal aberration involving RUNX1/AML1 is found in therapy-related myeloid malignancies. Translocation t(16;21)(q24;q22) that forms a RUNX1-CBFA2T3 fusion protein.;disease:Defects in RUNX1 are the cause of familial platelet disorder with associated myeloid malignancy (FPDMM) [MIM:601399]. FPDMM is an autosomal dominant disease characterized by qualitative and quantitative platelet defects; and propensity to develop acute myelogenous leukemia.;domain:A proline/serine/threonine rich region at the C-terminus is necessary for transcriptional activation of target genes.;function:CBF binds to the core site; 5'-PYGPYGGT-3'; of a number of enhancers and promoters; including murine leukemia virus; polyomavirus enhancer; T-cell receptor enhancers; LCK; IL-3 and GM-CSF promoters. The alpha subunit binds DNA and appears to have a role in the development of normal hematopoiesis. Isoform AML-1L interferes with the transactivation activity of RUNX1. Acts synergistically with ELF4 to transactivate the IL-3 promoter and with ELF2 to transactivate the mouse BLK promoter. Inhibits MYST4-dependent transcriptional activation.;PTM:Methylated.;PTM:Phosphorylated in its C-terminus upon IL-6 treatment. Phosphorylation enhances interaction with MYST3.;similarity:Contains 1 Runt domain.;subunit:Heterodimer with CBFB. RUNX1 binds DNA as a monomer and through the Runt domain. DNA-binding is increased by heterodimerization. Isoform AML-1L can neither bind DNA nor heterodimerize. Interacts with TLE1 and THOC4. Interacts with ELF1; ELF2 and SPI1. Interacts via its Runt domain with the ELF4 N-terminal region. Interaction with ELF2 isoform 2 (NERF-1a) may act to repress RUNX1-mediated transactivation. Interacts with MYST3 and MYST4. Interacts with SUV39H1; leading to abrogate the transactivating and DNA-binding properties of RUNX1.;tissue specificity:Expressed in all tissues examined except brain and heart. Highest levels in thymus; bone marrow and peripheral blood.;
Immunogen:
Synthesized peptide derived from human RUNX1 (Acetyl Lys24)
Isotyp:
IgG
Reaktivitäten:
Human, Mouse, Rat
Versandbedingungen:
Blue Ice
Quelle:
Rabbit
Lagerbedingungen:
-20[o]C
Hersteller:
ELK Biotechnology
Typ:
Antibodies: Polyclonal Antibody
Price enquiry form